ANN ARBOR, Mich., Oct. 1 /PRNewswire/ -- Assay Designs, Inc., a leading provider of immunoassay kits, antibodies, and reagents to the life sciences and translational research markets, announced two key additions to its senior leadership team:
- Michael Mullenix, PhD, has joined the company as Vice President,
Research and Development. Dr. Mullenix comes to Assay Designs from
Amgen in Thousand Oaks, CA, where he was a Principal Scientist in their
Clinical Immunology group, responsible for a team of scientists
dedicated to the development of GLP compliant immunoassays for
preclinical and clinical trials. Prior to joining Amgen, Dr. Mullenix
held a series of R&D leadership positions with Molecular Staging,
Becton Dickinson, and Strategic Diagnostics.
- Gabriella Szekely-Klepser, PhD, joined Assay Designs as Vice President,
Science and Technology. Dr. Szekely-Klepser was previously an Associate
Research Fellow at Pfizer Global R&D in Ann Arbor, where she was most
recently leader of the Translational Research Biomarker Implementation
and Biologics Bioanalytical Groups. Prior to her six years at Pfizer,
Dr. Szekely-Klepser held various R&D positions at 3M Corporation.
"We are thrilled at having Mike and Gabriella join Assay Designs," stated Dan Calvo, President and CEO. "Mike has a unique blend of assay development experience from Amgen, coupled with an extensive track record of launching innovative immunoassay kit and reagent products earlier in his career. He knows how to drive an innovative and productive R&D pipeline from concept to launch. Gabriella led the establishment and expansion of Pfizer's biomarker programs across many of its therapeutic areas. She also worked closely with several key CROs to translate and scale-up complex assays. Her experience in developing and validating biomarker assays, and her understanding of the critical success factors for these programs within drug development sponsors, are a perfect match with our growth strategy," continued Calvo.
"Mike and Gabriella are joining Assay Designs at a pivotal and exciting time," further stated Mr. Calvo. "Since April, we have expanded our commercial team with the addition of three key individuals: Maziar Younessian, Director of Marketing and formerly with Invitrogen, Dr. Dana Haley-Vicente, Senior Product Manager and formerly with Accelrys, and Robert Moynihan, Manager for our International business and formerly with Perkin Elmer Life Sciences. We have also promoted Dr. Rob Christener to the new role of General Manager for our growing reagents business, spear-headed by our Stressgen(R) product line."
Mr. Calvo continued, "With this new team in place, we are poised to expand our line of innovative kits and reagents in our core inflammation and steroids/hormone businesses, as well as expand our line of market-leading heat shock and oxidative stress reagents and kits under the Stressgen brand name. We have recently launched a line of unique, activation-state specific antibodies that distinguish between the active and passive forms of numerous GPCRs. Our new and expanded team will build upon this product portfolio, as well as drive the expansion of our business into the biomarker and clinical trial services space."
About Assay Designs, Inc.
Based in Ann Arbor, MI, Assay Designs develops, manufactures and markets immunoassay (ELISA) kits, antibodies, and proteins that are used for life sciences research. The company markets these products under the "Assay Designs" and "Stressgen" brand names. Researchers use its products to detect and quantify molecules that are important in inflammation, heat shock, cell signaling, and oxidative stress.
|SOURCE Assay Designs, Inc.|
Copyright©2007 PR Newswire.
All rights reserved